VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or high-risk MDS that has not responded to or come back after at least one round of chemotherapy.
- You have recovered from side effects of your last treatment, and your liver and kidneys are working well.
- You are not pregnant or breastfeeding, and you are willing to follow the study plan.
- You are at least 12 weeks from any major surgery, radiation, or other cancer treatments.
- You do not have other untreated cancers or serious health problems like uncontrolled diabetes or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) at lower doses plus a targeted drug called venetoclax for adults newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this reduced-intensity treatment is effective with fewer side effects.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Hear when a new Relapsed Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.